Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study.
Cross-walking
Dementia
Health related quality of life
Mapping algorithm
Preference based measures
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
accepted:
03
10
2020
pubmed:
18
10
2020
medline:
20
4
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
The Quality of Life Alzheimer's Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness analyses, utilities based on the EQ-5D are often required. We report a new mapping algorithm to obtain EQ-5D indices when only QoL-AD data are available. Different statistical models to estimate utility directly, or responses to individual EQ-5D questions (response mapping) from QoL-AD, were trialled for patient-rated and proxy-rated questionnaires. Model performance was assessed by root mean square error and mean absolute error. The response model using multinomial regression including age and sex, performed best in both the estimation dataset and an independent dataset. The recommended mapping algorithm allows researchers for the first time to estimate EQ-5D values from QoL-AD data, enabling cost-utility analyses using datasets where the QoL-AD but no utility measures were collected.
Identifiants
pubmed: 33068236
doi: 10.1007/s11136-020-02670-8
pii: 10.1007/s11136-020-02670-8
pmc: PMC7952290
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
867-879Subventions
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Références
Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer Report 2015. The Global Imapct of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends.: Alzeihmer's Disease International, 2015.
National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. 2018. https://www.nice.org.uk/guidance/ng97 Accessed 29 Aug 2018
Farina, N., Page, T. E., Daley, S., et al. (2017). Factors associated with the quality of life of family carers of people with dementia: A systematic review. Alzheimers Dement, 13(5), 572–81.
doi: 10.1016/j.jalz.2016.12.010
World Health Organisation. WHOQOL: Measuring Quality of Life. 2018. https://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/ Accessed 29 Aug 2018
Schölzel-Dorenbos CJM. Quality of life in dementia: From concept to practice: Radboud University Nijmegen; 2011.
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (1999). Quality of life in Alzheimer's disease: Patient and caregiver reports. Journal of Mental Health and Aging, 5(1), 21–32.
Smith, S. C., Lamping, D. L., Banerjee, S., et al. (2007). Development of a new measure of health-related quality of life for people with dementia: DEMQOL. Psychol Med, 37(5), 737–46.
doi: 10.1017/S0033291706009469
Brazier, J., & Dixon, S. (1995). The use of condition specific outcome measures in economic appraisal. Health Econ, 4(4), 255–64.
doi: 10.1002/hec.4730040402
Kind, P. (2001). Measuring quality of life in evaluating clinical interventions: An overview. Ann Med, 33(5), 323–7.
doi: 10.3109/07853890109002085
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. https://www.nice.org.uk/process/pmg9/chapter/the-reference-case Accessed 03 Sep 2018
Rowen, D., Mulhern, B., Banerjee, S., et al. (2012). Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-Proxy. Value Health, 15(2), 346–56.
doi: 10.1016/j.jval.2011.10.016
Mulhern B, Rowen D, Brazier J, et al. Development of DEMQOL-U and DEMQOL-PROXY-U: Generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation. Health Technol Assess 2013; 17(5): v-xv, 1-140.
Bruvik, F. K., Ulstein, I. D., Ranhoff, A. H., & Engedal, K. (2012). The quality of life of people with dementia and their family carers. Dementia and Geriatric Cognitive Disorders, 34(1), 7–14.
doi: 10.1159/000341584
McCarney, R., Fisher, P., Iliffe, S., et al. (2008). Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life and allied sciences, 23(12), 1222–30.
doi: 10.1002/gps.2055
Meeuwsen, E. J., Melis, R. J., Van Der Aa, G. C., et al. (2012). Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial. BMJ, 344, e3086.
doi: 10.1136/bmj.e3086
Spector, A., Thorgrimsen, L., Woods, B., et al. (2003). Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. The British Journal of Psychiatry, 183(3), 248–54.
doi: 10.1192/bjp.183.3.248
Moniz-Cook, E., Vernooij-Dassen, M., Woods, R., et al. (2008). A European consensus on outcome measures for psychosocial intervention research in dementia care. Aging and Mental Health, 12(1), 14–29.
doi: 10.1080/13607860801919850
Dakin, H., Abel, L., Burns, R., & Yang, Y. (2018). Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: An online database and application of the MAPS statement. Health Qual Life Outcomes, 16(1), 31.
doi: 10.1186/s12955-018-0857-3
Petrou, S., Rivero-Arias, O., Dakin, H., et al. (2015). The maps reporting statement for studies mapping onto generic preference-based outcome measures. Value Health, 18(7), A715–6.
doi: 10.1016/j.jval.2015.09.2702
Gallacher, J., de Reydet de Vulpillieres, F., Amzal, B., et al. (2019). Challenges for optimizing real-world evidence in Alzheimer's Disease: The ROADMAP project. Journal of Alzheimers Disease, 67(2), 495–501.
doi: 10.3233/JAD-180370
Kerpershoek, L., de Vugt, M., Wolfs, C., et al. (2016). Access to timely formal dementia care in Europe: Protocol of the Actifcare (ACcess to Timely Formal Care) study. BMC Health Services Research, 16(1), 423.
doi: 10.1186/s12913-016-1672-3
Handels, R. L., Aalten, P., Wolfs, C. A., et al. (2012). Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. BMC Neurology, 12, 72.
doi: 10.1186/1471-2377-12-72
Logsdon R, Gibbons LE, McCurry SM, Teri L. Quality of Life in Alzheimer’s Disease (QOL-AD). https://eprovide.mapi-trust.org/instruments/quality-of-life-in-alzheimer-s-disease#languages Accessed 21 Jun 2020.
Dichter, M. N., Wolschon, E. M., Meyer, G., & Kopke, S. (2016). Cross-cultural adaptation of the German version of the Quality of Life in Alzheimer's Disease scale—Nursing Home version (QoL-AD NH). International Psychogeriatry, 28(8), 1399–400.
doi: 10.1017/S1041610216000107
Romhild, J., Fleischer, S., Meyer, G., et al. (2018). Inter-rater agreement of the Quality of Life-Alzheimer's Disease (QoL-AD) self-rating and proxy rating scale: secondary analysis of RightTimePlaceCare data. Health Qual Life Outcomes, 16(1), 131.
doi: 10.1186/s12955-018-0959-y
Barrios, H., Verdelho, A., Narciso, S., Goncalves-Pereira, M., Logsdon, R., & de Mendonca, A. (2013). Quality of life in patients with cognitive impairment: Validation of the quality of life-alzheimer’s disease scale in Portugal. International Psychogeriatrics, 25(7), 1085–96.
doi: 10.1017/S1041610213000379
Wolak, A., Novella, J. L., Drame, M., et al. (2009). Transcultural adaptation and psychometric validation of a French-language version of the QoL-AD. Aging Mental Health, 13(4), 593–600.
doi: 10.1080/13607860902774386
Stypa V, Haussermann P, Fleiner T, Neumann S. Validity and Reliability of the German Quality of Life-Alzheimer's Disease (QoL-AD) Self-Report Scale. Journal Alzheimers Disease 2020.
Dolan, P., & Roberts, J. (2002). Modelling valuations for Eq-5d health states: an alternative model using differences in valuations. Medical Care, 40(5), 442–6.
doi: 10.1097/00005650-200205000-00009
Feng, Y., Devlin, N. J., Shah, K. K., Mulhern, B., & van Hout, B. (2018). New methods for modelling EQ-5D-5L value sets: An application to English data. Health Economics, 27(1), 23–38.
doi: 10.1002/hec.3560
van Hout, B., Janssen, M. F., Feng, Y. S., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health, 15(5), 708–15.
doi: 10.1016/j.jval.2012.02.008
Dakin, H., Gray, A., & Murray, D. (2013). Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Qual Life Res, 22(3), 683–94.
doi: 10.1007/s11136-012-0189-4
Howland, M., Allan, K. C., Carlton, C. E., Tatsuoka, C., Smyth, K. A., & Sajatovic, M. (2017). Patient-rated versus proxy-rated cognitive and functional measures in older adults. Patient Related Outcome Measures, 8, 33–42.
doi: 10.2147/PROM.S126919
Bosboom, P. R., Alfonso, H., Eaton, J., & Almeida, O. P. (2012). Quality of life in Alzheimer's disease: Different factors associated with complementary ratings by patients and family carers. International Psychogeriatrics, 24(5), 708–21.
doi: 10.1017/S1041610211002493
Leurent, B., Gomes, M., & Carpenter, J. R. (2018). Missing data in trial-based cost-effectiveness analysis: An incomplete journey. Health Economics, 27(6), 1024–40.
doi: 10.1002/hec.3654
Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. L. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics, 11(2), 215–25.
doi: 10.1007/s10198-009-0168-z
National Institute for Health and Care Excellence. Position statement on use of the EQ-5D-5L valuation set for England (updated November 2018). 2018. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l Accessed 29 Nov 2018.
Dakin, H., Petrou, S., Haggard, M., Benge, S., & Williamson, I. (2010). Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire. Qual Life Res, 19(1), 65–80.
doi: 10.1007/s11136-009-9558-z
Shearer, J., Green, C., Ritchie, C. W., & Zajicek, J. P. (2012). Health state values for use in the economic evaluation of treatments for Alzheimer’s disease. Drugs & Aging, 29(1), 31–43.
doi: 10.2165/11597380-000000000-00000
Banerjee, S., Samsi, K., Petrie, C. D., et al. (2009). What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. International Journal of Geriatric Psychiatry: A Journal of the Psychiatry of Late Life and Allied Sciences, 24(1), 15–24.
doi: 10.1002/gps.2090
Sheehan, B. D., Lall, R., Stinton, C., et al. (2012). Patient and proxy measurement of quality of life among general hospital in-patients with dementia. Aging Mental Health, 16(5), 603–7.
doi: 10.1080/13607863.2011.653955
Vogel, A., Mortensen, E. L., Hasselbalch, S. G., Andersen, B. B., & Waldemar, G. (2006). Patient versus informant reported quality of life in the earliest phases of Alzheimer's disease. International Journal of Geriatric Psychiatry: A journal of the Psychiatry of Late Life and Allied Sciences, 21(12), 1132–8.
doi: 10.1002/gps.1619
Lacey, L., Bobula, J., Rüdell, K., Alvir, J., & Leibman, C. (2015). Quality of life and utility measurement in a large clinical trial sample of patients with mild to moderate Alzheimer’s disease: determinants and level of changes observed. Value in Health, 18(5), 638–45.
doi: 10.1016/j.jval.2015.03.1787
Wailoo, A. J., Hernandez-Alava, M., Manca, A., et al. (2017). Mapping to estimate health-state utility from non-preference-based outcome measures: An ISPOR good practices for outcomes research task force report. Value Health, 20(1), 18–27.
doi: 10.1016/j.jval.2016.11.006